ChinaSinopharm GroupNew crown vaccine included in WHO's emergency use list
On May 7, local time, WHO announced that a new crown vaccine from China National Pharmaceutical Group was included in WHO's emergency use list. The vaccine becomes the sixth vaccine to be included in the WHO's emergency use list.
WHO Director-General Tedros said at a press conference on the same day that WHO included a vaccine developed by China National Pharmaceutical Group China Bio-Beijing Institute of Biological Products on the emergency use list. This vaccine meets the needs of the world. WHO standards for the safety, efficacy and quality of Covid-19 vaccines. Tedros said that this will allow the WHO-led "New Coronary Pneumonia Vaccine Implementation Plan" (COVAX) to purchase Sinopharm's new crown vaccine, enhance the confidence of relevant national drug regulatory agencies to approve the vaccine, and speed up Sinopharm's vaccine import and export. Inoculation speed.
Tedros (data map)
The WHO immunization strategic advisory group recommends that adults over the age of 18 can receive two doses of Sinopharm's new crown vaccine. According to WHO standards, only those with an effective rate of more than 50%, preferably close to or higher than 70%, and with good safety can be included in the emergency use list.
Alejandro Clavioto, Chairman of the WHO Strategic Advisory Group of Immunization Experts, said at a press conference earlier that the vaccine data submitted by Sinopharm and Sinovac clearly show that The protection of the vaccines of the two companies The potency meets WHO requirements, and the data submitted by the two companies also show the safety of the two vaccines, which do not cause harm to humans.
(data map)
WHO has previously authorized the use of several new crown vaccines, including The vaccine jointly developed by Pfizer Pharmaceuticals and German Biotech, and the vaccine jointly developed by AstraZeneca and Oxford University , the vaccine developed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson in the United States, and the new crown vaccine developed by Moderna in the United States. The new crown vaccine of Sinopharm Group is the first inactivated vaccine included in the WHO emergency use list. It is reported that a new crown vaccine developed by China Kexing has also entered the final stage of the WHO emergency use authorization evaluation.
People's Daily client screenshot
Extra
Japanese media: India and the United States are frustrated, the world is more and more dependent on China's vaccine Seeking a vaccine The pandemic ravages India's ability to fulfill supply agreements. In this case, the world is rapidly becoming more and more dependent on China's vaccines.
Over the past few weeks, leaders of some of the world's most populous countries have turned to China for more vaccines. If the World Health Organization (WHO) approves the use of vaccines by China Kexing and Sinopharm, so that developing countries in Asia, Africa and Latin America can obtain them through the "New Crown Vaccine Implementation Plan", the demand will further increase. "China is not just the biggest exporter. In many countries, China is the only choice.""
(data map)
The United States and Europe are making slow progress in responding to the epidemic, while India, Brazil and other epidemic hotspots are out of control. Under such circumstances, China, as a vaccine supplier, continues to increase its geopolitical influence. The crisis in India This has exacerbated supply difficulties and prompted many countries to turn to China. At the same time, the United States has been focusing on its own vaccinations for months, and has been strongly criticized for hoarding vaccines to undermine the global fight against the epidemic. For many countries, from Uruguay to Senegal to Indonesia, there is little other place to turn to but China, which has exported about 240 million vaccine doses, more than all other countries, according to scientific information and analysis firm Airfinity combined and pledged to deliver another 500 million doses. India was the world's third largest supplier of vaccines after China and EU until the recent devastating outbreak forced India to halt most of its output. WHO is assessing Data on vaccines in China. Approval of the Chinese vaccine will have an immediate effect on the many countries waiting to provide vaccines to their citizens. City University of Hong KongAssociate Professor Nicholas Thomas, who has edited books on global health and foreign policy said, WHO Organizing the approval of China's vaccine will help strengthen China's regional influence and authority in the medium term. China's foreign minister promised in a phone call with his South Asian counterparts last week that China would provide vaccines to countries that have been reliant on India. The same day , China's defense minister talked with Bangladesh about military cooperation. After that, the country approved the emergency use of Sinopharm's vaccine because most of the vaccines ordered from India failed to arrive.The Indonesian government has also approved the emergency use of the Chinese vaccine. The country's epidemiologist Pandu Riono said: "It is clear that India's export ban has made Indonesia more and more dependent on China's vaccine supply." . Export delays in India cost Philippines largest vaccine order. The Philippine president this week scolded his top diplomat for abusing China on Twitter. The Philippine government is currently negotiating with Sinovac on vaccine deliveries. Duterte said: "China is still our benefactor." Some countries that have been relying on China's vaccines, such as Chile, have also acted accordingly. (translated by Qiao Heng) Source: People's Daily Client/Zhang Penghui, Global Times-World Wide Web
